AU743824B2 - Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease - Google Patents

Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease Download PDF

Info

Publication number
AU743824B2
AU743824B2 AU33796/99A AU3379699A AU743824B2 AU 743824 B2 AU743824 B2 AU 743824B2 AU 33796/99 A AU33796/99 A AU 33796/99A AU 3379699 A AU3379699 A AU 3379699A AU 743824 B2 AU743824 B2 AU 743824B2
Authority
AU
Australia
Prior art keywords
antibody
cells
cell
treatment
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
AU33796/99A
Other languages
English (en)
Other versions
AU3379699A (en
Inventor
Christopher M. Burns
Randolph J Noelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of AU3379699A publication Critical patent/AU3379699A/en
Application granted granted Critical
Publication of AU743824B2 publication Critical patent/AU743824B2/en
Anticipated expiration legal-status Critical
Withdrawn - After Issue legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU33796/99A 1998-04-03 1999-04-02 Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease Withdrawn - After Issue AU743824B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
US09/054488 1998-04-03
PCT/US1999/007321 WO1999051258A1 (en) 1998-04-03 1999-04-02 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
AU3379699A AU3379699A (en) 1999-10-25
AU743824B2 true AU743824B2 (en) 2002-02-07

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33796/99A Withdrawn - After Issue AU743824B2 (en) 1998-04-03 1999-04-02 Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease

Country Status (9)

Country Link
EP (1) EP1067954A4 (OSRAM)
JP (1) JP2002510643A (OSRAM)
KR (1) KR20010072564A (OSRAM)
CN (2) CN100352497C (OSRAM)
AU (1) AU743824B2 (OSRAM)
HU (1) HUP0101689A3 (OSRAM)
NO (1) NO20004966L (OSRAM)
TW (1) TWI224969B (OSRAM)
WO (1) WO1999051258A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1996023071A2 (en) * 1995-01-26 1996-08-01 Bristol-Myers Squibb Company MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
NZ337072A (en) * 1997-01-10 2000-12-22 Biogen Inc use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
AU5623398A (en) * 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1996023071A2 (en) * 1995-01-26 1996-08-01 Bristol-Myers Squibb Company MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY

Also Published As

Publication number Publication date
CN1173735C (zh) 2004-11-03
HUP0101689A3 (en) 2004-08-30
NO20004966L (no) 2000-12-04
AU3379699A (en) 1999-10-25
EP1067954A1 (en) 2001-01-17
EP1067954A4 (en) 2004-08-18
CN100352497C (zh) 2007-12-05
TWI224969B (en) 2004-12-11
NO20004966D0 (no) 2000-10-02
JP2002510643A (ja) 2002-04-09
CN1757413A (zh) 2006-04-12
KR20010072564A (ko) 2001-07-31
HUP0101689A2 (hu) 2001-08-28
WO1999051258A1 (en) 1999-10-14
CN1303301A (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
US7445781B2 (en) Anti-CD40CR MR1 antibody
EP0751781B1 (en) Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic disorders
AU696235B2 (en) Anti-GP39 antibodies and uses therefor
TWI222453B (en) Ligand for herpes simplex virus entry mediator and methods of use
US5942229A (en) Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent
US6472510B1 (en) CD40 receptor ligands
AU734853B2 (en) Methods of prolonged suppression of humoral immunity
CA2391530A1 (en) Tr3-specific binding agents and methods for their use
AU3379699A (en) Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
US20020058037A1 (en) Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease
ES2301164T3 (es) Slam, antigeno coestimulador de la superficie de celulas t.
Ozaki et al. Antigen specificity of dual reactive T hybridomas determines the requirement for CD40 ligand-CD40 interactions
HK1067887A (en) Antibodies that bind the cd40cr receptor
MXPA93000768A (en) Cd40cr receptor and ligands therefor
AU779647B2 (en) Methods of prolonged suppression of humoral immunity

Legal Events

Date Code Title Description
CB Opposition filed

Opponent name: BIOGEN, INC